Exane Derivatives’s Merck MRK Stock Holding History

Exane Derivatives’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$5.91M	Sell	64,879 -3,015	-4%	-$267K	3.4%	3
2022 Q1	$5.57M	Buy	67,894 +10,456	+18%	+$824K	1.57%	7
2021 Q4	$4.4M	Sell	57,438 -4,987	-8%	-$397K	1.07%	13
2021 Q3	$4.69M	Buy	62,425 +8,947	+17%	+$680K	1.13%	12
2021 Q2	$4.15M	Sell	53,478 -433	-0.8%	-$32.2K	0.94%	20
2021 Q1	$3.97M	Buy	53,911 +3,988	+8%	+$294K	1.13%	18
2020 Q4	$3.9M	Sell	49,923 -28,341	-36%	-$2.17M	1.15%	17
2020 Q3	$6.19M	Buy	78,264 +21,538	+38%	+$1.69M	1.79%	11
2020 Q2	$4.19M	Sell	56,726 -41,310	-42%	-$3.11M	1.12%	21
2020 Q1	$7.2M	Buy	98,036 +40,729	+71%	+$3.2M	2.01%	11
2019 Q4	$5M	Buy	57,307 +1,656	+3%	+$136K	0.93%	21
2019 Q3	$4.47M	Buy	55,651 +1,260	+2%	+$101K	0.8%	21
2019 Q2	$4.35M	Sell	54,391 -3,496	-6%	-$268K	0.76%	25
2019 Q1	$4.59M	Buy	57,887 +9,719	+20%	+$727K	0.91%	22
2018 Q4	$3.51M	Sell	48,168 -9,794	-17%	-$691K	0.63%	38
2018 Q3	$3.93M	Buy	57,962 +47,854	+473%	+$3.05M	0.74%	29
2018 Q2	$590K	Buy	+10,108	New	+$570K	0.1%	164
2016 Q3	–	Sell	-9,304	Closed	-$511K	–	649
2016 Q2	$511K	Sell	9,304 -796	-8%	-$42.4K	0.08%	128
2016 Q1	$510K	Sell	10,100 -6,557	-39%	-$321K	0.07%	134
2015 Q4	$839K	Buy	16,657 +5,724	+52%	+$289K	0.12%	88
2015 Q3	$515K	Buy	+10,933	New	+$581K	0.07%	124
2015 Q2	–	Sell	-21,120	Closed	-$1.16M	–	543
2015 Q1	$1.16M	Buy	21,120 +6,159	+41%	+$349K	0.13%	91
2014 Q4	$811K	Buy	+14,961	New	+$834K	0.11%	111

Other funds holding MRK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Exane Derivatives's MRK Position: Q2 2022 in Review

Exane Derivatives reduced its Merck (MRK) stake by 4.4% in Q2 2022, selling an estimated $267K and leaving 64,879 shares worth $5.91M. The position accounts for 3.4% of the portfolio, ranked #3.

Exane Derivatives first reported a position in MRK in Q4 2014 and has held it in 23 quarters since. The position peaked at $7.2M in Q1 2020. 3,014 funds tracked by Wall St. Rank hold MRK as of Q2 2022.

Exane Derivatives held 64,879 shares of Merck worth $5.91M as of Q2 2022.
Exane Derivatives sold 3,015 Merck shares in Q2 2022, an estimated $267K.
Merck made up 3.4% of Exane Derivatives's portfolio in Q2 2022, its #3 holding.
Exane Derivatives first reported a position in Merck in Q4 2014 and has held it in 23 quarters since.
Exane Derivatives's Merck position peaked at $7.2M in Q1 2020.
3,014 funds tracked by Wall St. Rank held Merck as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.